567 Eli Lilly and Company $LLY Shares Acquired by MRA Advisory Group

MRA Advisory Group increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 194.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 859 shares of the company’s stock after acquiring an additional 567 shares during the quarter. MRA Advisory Group’s holdings in Eli Lilly and Company were worth $994,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Lake Hills Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $1,058,000. Worth Asset Management LLC increased its position in Eli Lilly and Company by 9.4% in the third quarter. Worth Asset Management LLC now owns 1,786 shares of the company’s stock worth $2,067,000 after buying an additional 153 shares during the period. Matrix Trust Co lifted its stake in Eli Lilly and Company by 10.4% in the third quarter. Matrix Trust Co now owns 2,931 shares of the company’s stock valued at $3,391,000 after buying an additional 275 shares during the last quarter. Crumly & Associates Inc. lifted its stake in Eli Lilly and Company by 11.2% in the third quarter. Crumly & Associates Inc. now owns 882 shares of the company’s stock valued at $1,021,000 after buying an additional 89 shares during the last quarter. Finally, Weaver Consulting Group boosted its holdings in shares of Eli Lilly and Company by 32.1% during the third quarter. Weaver Consulting Group now owns 728 shares of the company’s stock valued at $842,000 after acquiring an additional 177 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $40.26 during trading hours on Wednesday, hitting $1,197.74. 1,234,705 shares of the company traded hands, compared to its average volume of 2,968,515. The firm has a market cap of $1.13 trillion, a P/E ratio of 40.18, a P/E/G ratio of 1.40 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm’s 50-day simple moving average is $1,173.98 and its two-hundred day simple moving average is $1,092.69. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same period in the prior year, the business posted $6.31 EPS. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts forecast that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LLY. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada boosted their target price on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research note on Wednesday, July 8th. Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, September 15th. Finally, Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,312.36.

Insider Activity

In related news, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 over the last 90 days. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts remain optimistic about Lilly’s obesity franchise. Articles highlight potential growth from Zepbound and Mounjaro, as well as next-generation candidate retatrutide, which has produced greater average weight loss in trials and could be filed with the FDA in early 2027. Oral GLP-1 candidate Foundayo also reportedly delivered better weight loss and blood-sugar control than oral semaglutide in a company analysis, supporting expectations for a broader, more convenient market. Eli Lilly: Buy The GLP-1 Growth Premium
• Positive Sentiment: Investors are also pricing in growth outside obesity. Lilly’s oncology, immunology and neuroscience businesses are expanding, while an FDA orphan-drug designation for experimental cancer treatment olomorasib may provide development incentives and future exclusivity. The company also completed early-stage trials for a basal-insulin candidate and advanced its drug-discovery collaboration with Gate Bioscience, potentially worth more than $870 million. Eli Lilly Scores FDA Win for Pancreatic Cancer Drug
• Neutral Sentiment: Several market commentaries describe positive momentum heading into third-quarter earnings and argue that Lilly’s growth outlook justifies a premium multiple. Recent performance has outpaced the broader market, and one valuation analysis sees additional upside from pipeline growth. These are largely opinion-based catalysts rather than new financial guidance. Eli Lilly: Quiet Momentum Builds Into Q3 Earnings
• Negative Sentiment: The main concern is valuation: LLY trades at roughly 40 times trailing earnings, leaving limited room for disappointing results. Commentary also warns that falling U.S. prices for Zepbound and Mounjaro could pressure margins and that investor expectations have become excessive. New WHO childhood-obesity guidelines emphasize lifestyle and public-health measures, potentially limiting near-term expectations for pharmaceutical treatment in younger patients. WHO Childhood Obesity Guidelines

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.